Consolidated Statements of Cash Flows $ in Thousands	12 Months Ended
	Dec. 31, 2025 USD ($)	Dec. 31, 2024 USD ($)
Cash flows used in operating activities:
Net loss	$ (104,994)	$ (105,316)
Adjustments to reconcile net loss to cash used in operating activities:
Stock-based compensation expense	19,099	29,662
Impairment loss on right-of-use asset	10,733	0
Depreciation and amortization	1,959	1,818
Reduction in carrying amount of right-of-use asset	6,434	6,421
Accretion of premium on marketable securities	(2,742)	(5,396)
Other	99	6
Changes in operating assets and liabilities:
Accounts receivable	701	8,697
Prepaid expenses and other current and long-term assets	1,144	(4,328)
Accounts payable	(468)	(119)
Accrued expenses and other current liabilities	(6,049)	(1,267)
Operating lease liability	(5,774)	(5,219)
Deferred revenue	(18,836)	9,884
Net cash used in operating activities	(98,694)	(65,157)
Cash flows provided by investing activities:
Proceeds from maturities of marketable securities	219,080	233,231
Purchase of marketable securities	(227,074)	(284,321)
Purchases of property and equipment	(607)	(180)
Net cash used in investing activities	(8,601)	(51,270)
Cash flows provided by financing activities:
Proceeds from exercises of stock options	107	778
Payments for repurchase of common stock for tax withholding	(193)	(194)
Other	274	382
Net cash provided by financing activities	126,399	45,336
Net change in cash, cash equivalents and restricted cash	19,104	(71,091)
Cash, cash equivalents and restricted cash at beginning of period	58,942	130,033
Cash, cash equivalents and restricted cash at end of period	78,046	58,942
Reconciliation of cash, cash equivalents and restricted cash:
Cash, cash equivalents and restricted cash at end of year	78,046	58,942
Less: restricted cash	(3,443)	(3,443)
Cash and cash equivalents at end of the year	74,603	55,499
Underwritten Offering
Cash flows provided by financing activities:
Proceeds from issuance of common stock	116,870	0
At-The-Market Equity Program
Cash flows provided by financing activities:
Proceeds from issuance of common stock	9,341	24,370
Betta Pharma Stock Purchase Agreement
Cash flows provided by financing activities:
Proceeds from issuance of common stock	$ 0	$ 20,000